PedAM

Pediatric Disease Annotations & Medicines


	liver neoplasms

Disease ID	721
Disease	liver neoplasms
Definition	Tumors or cancer of the LIVER.
Synonym	hepatic neopl hepatic neoplasia hepatic neoplasias hepatic neoplasm hepatic neoplasms hepatic tumor hepatic tumors hepatic tumour hepatic tumours hepatics tumors hepatoma liver neopl liver neoplasm liver neoplasms [disease/finding] liver tumor liver tumors liver tumour liver tumours liver--tumors neopl hepatic neopl liver neoplasm liver neoplasm of liver neoplasm of liver (disorder) neoplasm of the liver neoplasm, hepatic neoplasm, liver neoplasms, hepatic neoplasms, liver tumor liver tumor of liver tumour liver tumour of liver
OMIM	OMIM:114550
DOID	DOID:916 DOID:684 DOID:3571
UMLS	C0023903
MeSH	D008113
SNOMED-CT	SNOMEDCT_US_2016_09_01:126851005
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:74) C0019158 \| hepatitis \| 16 C0019204 \| hepatocellular carcinoma \| 10 C0019163 \| hepatitis b \| 6 C0023890 \| cirrhosis \| 6 C0019196 \| hepatitis c \| 6 C0023890 \| liver cirrhosis \| 6 C0011847 \| diabetes \| 4 C0155773 \| portal vein thrombosis \| 3 C0042769 \| virus infection \| 3 C0040053 \| thrombosis \| 3 C0206624 \| hepatoblastoma \| 3 C0206698 \| cholangiocarcinoma \| 3 C0206669 \| hepatocellular adenoma \| 2 C0041296 \| tuberculosis \| 2 C1261473 \| sarcoma \| 2 C0023895 \| liver disease \| 2 C0001430 \| adenoma \| 2 C0028754 \| obesity \| 2 C0023903 \| hepatic tumor \| 2 C0018916 \| hemangioma \| 2 C0023903 \| liver cancer \| 2 C0149925 \| small cell carcinoma \| 2 C0008311 \| cholangitis \| 2 C0024623 \| gastric cancer \| 2 C0043119 \| adult progeria \| 1 C0001418 \| adenocarcinoma \| 1 C0007137 \| epidermoid carcinoma \| 1 C0019204 \| liver carcinoma \| 1 C0013502 \| hydatid cysts \| 1 C0024299 \| lymphoma \| 1 C0494165 \| liver metastases \| 1 C0013502 \| hydatid cyst \| 1 C0345907 \| hepatic angiosarcoma \| 1 C0004623 \| bacterial infection \| 1 C0153676 \| lung metastasis \| 1 C0020437 \| hypercalcemia \| 1 C0879615 \| stromal tumor \| 1 C0279661 \| pancreatic acinar cell carcinoma \| 1 C0009402 \| colorectal cancer \| 1 C0494165 \| hepatic metastases \| 1 C0019163 \| hepatitis b infection \| 1 C0041313 \| hepatic tuberculosis \| 1 C0751498 \| sigmoid cancer \| 1 C0019204 \| hepatoma \| 1 C0010481 \| cushing syndrome \| 1 C0030305 \| pancreatitis \| 1 C0238198 \| gastrointestinal stromal tumor \| 1 C0442874 \| neuropathy \| 1 C0030499 \| parasitic disease \| 1 C0086692 \| benign neoplasm \| 1 C0010481 \| cushing's syndrome \| 1 C0007113 \| rectal cancer \| 1 C0021843 \| intestinal obstruction \| 1 C0005411 \| biliary atresia \| 1 C0878544 \| cardiomyopathy \| 1 C0019284 \| diaphragmatic hernia \| 1 C0021843 \| intestinal obstructions \| 1 C0034013 \| precocious puberty \| 1 C0043119 \| werner syndrome \| 1 C0241910 \| autoimmune hepatitis \| 1 C0023903 \| liver tumor \| 1 C0002766 \| analgesia \| 1 C0242379 \| lung cancer \| 1 C0020456 \| hyperglycemia \| 1 C0040053 \| thrombus \| 1 C0008350 \| cholelithiasis \| 1 C0031117 \| peripheral neuropathy \| 1 C0007102 \| colon cancer \| 1 C0030499 \| parasitic diseases \| 1 C0149521 \| chronic pancreatitis \| 1 C0006625 \| cachectic \| 1 C0018920 \| cavernous hemangioma \| 1 C0020538 \| hypertension \| 1 C0023891 \| alcoholic liver cirrhosis \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:111) TNF \| 7124 \| CTD_human RAF1 \| 5894 \| CTD_human PDRG1 \| 81572 \| CTD_human TP53 \| 7157 \| CTD_human SIX3 \| 6496 \| CTD_human STAT3 \| 6774 \| CTD_human PTPRO \| 5800 \| CTD_human HCFC1 \| 3054 \| CTD_human MYC \| 4609 \| CTD_human IFT88 \| 8100 \| CTD_human HMOX1 \| 3162 \| CTD_human PPARA \| 5465 \| CTD_human JUN \| 3725 \| CTD_human IGF2 \| 3481 \| CTD_human GPX3 \| 2878 \| CTD_human CSF2 \| 1437 \| CTD_human HRAS \| 3265 \| CTD_human TRIO \| 7204 \| CTD_human TNFSF10 \| 8743 \| CTD_human ESR1 \| 2099 \| CTD_human NDRG1 \| 10397 \| CTD_human IL12B \| 3593 \| CTD_human NFE2L2 \| 4780 \| CTD_human NR1H4 \| 9971 \| CTD_human PRICKLE2 \| 166336 \| CTD_human MYO5B \| 4645 \| CTD_human LTF \| 4057 \| CTD_human NUDT7 \| 283927 \| CTD_human ATP7B \| 540 \| CTD_human ABL1 \| 25 \| CTD_human APCS \| 325 \| CTD_human BRAF \| 673 \| CTD_human CSF3 \| 1440 \| CTD_human CLSTN2 \| 64084 \| CTD_human TCF4 \| 6925 \| CTD_human ANXA2 \| 302 \| CTD_human CYP2E1 \| 1571 \| CTD_human HGF \| 3082 \| CTD_human CDKN2A \| 1029 \| CTD_human GNMT \| 27232 \| CTD_human RTP3 \| 83597 \| CTD_human FST \| 10468 \| CTD_human ITIH1 \| 3697 \| CTD_human CTNNB1 \| 1499 \| CTD_human PPARG \| 5468 \| CTD_human KRAS \| 3845 \| CTD_human CRABP1 \| 1381 \| CTD_human NR1I3 \| 9970 \| CTD_human PTER \| 9317 \| CTD_human SLC11A2 \| 4891 \| CTD_human PQLC3 \| 130814 \| CTD_human FLCN \| 201163 \| CTD_human IL2 \| 3558 \| CTD_human NOP16 \| 51491 \| CTD_human SERPINE1 \| 5054 \| CTD_human CDKN1B \| 1027 \| CTD_human DACT2 \| 168002 \| CTD_human CCR4 \| 1233 \| CTD_human WDR17 \| 116966 \| CTD_human KRT8 \| 3856 \| CTD_human GSTM1 \| 2944 \| CTD_human TGFA \| 7039 \| CTD_human FHIT \| 2272 \| CTD_human ATF3 \| 467 \| CTD_human NAT2 \| 10 \| CTD_human GJB1 \| 2705 \| CTD_human AHR \| 196 \| CTD_human PRKCE \| 5581 \| CTD_human SLC40A1 \| 30061 \| CTD_human ACOT1 \| 641371 \| CTD_human SNHG11 \| 128439 \| CTD_human ZDHHC2 \| 51201 \| CTD_human SCD \| 6319 \| CTD_human EXOSC2 \| 23404 \| CTD_human UGDH \| 7358 \| CTD_human DDX54 \| 79039 \| CTD_human ANXA4 \| 307 \| CTD_human HEBP2 \| 23593 \| CTD_human ANXA7 \| 310 \| CTD_human IFNA1 \| 3439 \| CTD_human ADAMTS17 \| 170691 \| CTD_human TTC39A \| 22996 \| CTD_human CIDEA \| 1149 \| CTD_human CCDC134 \| 79879 \| CTD_human DPP10 \| 57628 \| CTD_human TTLL9 \| 164395 \| CTD_human YIF1A \| 10897 \| CTD_human PLS1 \| 5357 \| CTD_human IL12A \| 3592 \| CTD_human MAPK14 \| 1432 \| CTD_human HERC3 \| 8916 \| CTD_human SPATA21 \| 374955 \| CTD_human CPT1B \| 1375 \| CTD_human TNK2 \| 10188 \| CTD_human PSMA4 \| 5685 \| CTD_human GADL1 \| 339896 \| CTD_human BTBD11 \| 121551 \| CTD_human SRMS \| 6725 \| CTD_human SLC38A9 \| 153129 \| CTD_human TMEM132D \| 121256 \| CTD_human HSDL2 \| 84263 \| CTD_human ZSCAN22 \| 342945 \| CTD_human LINGO2 \| 158038 \| CTD_human WSCD1 \| 23302 \| CTD_human DCD \| 117159 \| CTD_human KRT18 \| 3875 \| CTD_human CHN2 \| 1124 \| CTD_human MIR29A \| 407021 \| CTD_human HIGD2A \| 192286 \| CTD_human NUDCD3 \| 23386 \| CTD_human EFNB2 \| 1948 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:50) 54474 \| KRT20 \| DISEASES 3956 \| LGALS1 \| DISEASES 7249 \| TSC2 \| DISEASES 1048 \| CEACAM5 \| DISEASES 51185 \| CRBN \| DISEASES 2678 \| GGT1 \| DISEASES 968 \| CD68 \| DISEASES 2538 \| G6PC \| DISEASES 3337 \| DNAJB1 \| DISEASES 271 \| AMPD2 \| DISEASES 2184 \| FAH \| DISEASES 4072 \| EPCAM \| DISEASES 1119 \| CHKA \| DISEASES 7078 \| TIMP3 \| DISEASES 1513 \| CTSK \| DISEASES 10 \| NAT2 \| DISEASES 4838 \| NODAL \| DISEASES 3815 \| KIT \| DISEASES 4286 \| MITF \| DISEASES 1581 \| CYP7A1 \| DISEASES 51181 \| DCXR \| DISEASES 6504 \| SLAMF1 \| DISEASES 9435 \| CHST2 \| DISEASES 6868 \| ADAM17 \| DISEASES 947 \| CD34 \| DISEASES 5591 \| PRKDC \| DISEASES 7030 \| TFE3 \| DISEASES 5324 \| PLAG1 \| DISEASES 3855 \| KRT7 \| DISEASES 64782 \| AEN \| DISEASES 7127 \| TNFAIP2 \| DISEASES 23583 \| SMUG1 \| DISEASES 10164 \| CHST4 \| DISEASES 1499 \| CTNNB1 \| DISEASES 55107 \| ANO1 \| DISEASES 11186 \| RASSF1 \| DISEASES 2547 \| XRCC6 \| DISEASES 4151 \| MB \| DISEASES 4311 \| MME \| DISEASES 3880 \| KRT19 \| DISEASES 1380 \| CR2 \| DISEASES 116496 \| FAM129A \| DISEASES 1041 \| CDSN \| DISEASES 2315 \| MLANA \| DISEASES 2719 \| GPC3 \| DISEASES 983 \| CDK1 \| DISEASES 174 \| AFP \| DISEASES 272 \| AMPD3 \| DISEASES 728441 \| GGT2 \| DISEASES 270 \| AMPD1 \| DISEASES
Locus	(Waiting for update.)

Disease ID	721
Disease	liver neoplasms
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:52) HP:0002664 \| Neoplasia \| 48 HP:0012115 \| Liver inflammation \| 16 HP:0030731 \| Carcinoma \| 14 HP:0001402 \| Hepatocellular carcinoma \| 10 HP:0001394 \| Hepatic cirrhosis \| 6 HP:0200123 \| Chronic liver inflammation \| 4 HP:0001399 \| Liver failure \| 4 HP:0030242 \| Blood clot in portal vein \| 3 HP:0030153 \| Cholangiocarcinoma \| 3 HP:0002896 \| Liver cancer \| 3 HP:0002884 \| Hepatoblastoma \| 3 HP:0100523 \| Hepatic abscess \| 2 HP:0012378 \| Fatigue \| 2 HP:0012126 \| Gastric cancer \| 2 HP:0002202 \| Pleural effusion \| 2 HP:0100242 \| Sarcoma \| 2 HP:0030151 \| Cholangitis \| 2 HP:0001028 \| Strawberry mark \| 2 HP:0012028 \| Hepatocellular adenoma \| 2 HP:0001513 \| Obesity \| 2 HP:0002240 \| Enlarged liver \| 2 HP:0002835 \| Aspiration \| 2 HP:0001410 \| Decreased liver function \| 2 HP:0005214 \| Bowel obstruction \| 1 HP:0003072 \| Hypercalcemia \| 1 HP:0001048 \| Cavernous angioma \| 1 HP:0000969 \| Dropsy \| 1 HP:0006280 \| Chronic pancreas inflammation \| 1 HP:0002665 \| Lymphoma \| 1 HP:0100723 \| Gastrointestinal stroma tumor \| 1 HP:0100762 \| Hemobilia \| 1 HP:0001397 \| Hepatic steatosis \| 1 HP:0003003 \| Colon cancer \| 1 HP:0003287 \| Abnormality of mitochondrial metabolism \| 1 HP:0001638 \| Cardiomyopathy \| 1 HP:0008236 \| Isosexual precocious puberty \| 1 HP:0000826 \| Precocious puberty \| 1 HP:0001541 \| Ascites \| 1 HP:0002094 \| Dyspnea \| 1 HP:0000776 \| Diaphragmatic hernia \| 1 HP:0003073 \| Hypoalbuminaemia \| 1 HP:0001081 \| Gallstones \| 1 HP:0009830 \| Peripheral neuritis \| 1 HP:0009726 \| Renal neoplasm \| 1 HP:0000822 \| Hypertension \| 1 HP:0001733 \| Pancreatic inflammation \| 1 HP:0200058 \| Angiosarcoma \| 1 HP:0004787 \| Fulminant hepatitis \| 1 HP:0001578 \| Hypercortisolism \| 1 HP:0100820 \| Glomerulopathy \| 1 HP:0005912 \| Biliary duct atresia \| 1 HP:0003074 \| High blood glucose \| 1

Disease ID	721
Disease	liver neoplasms
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:7) C0009450 \| infection \| 6 C0019204 \| hepatocellular carcinoma \| 5 C0426768 \| o sign \| 4 C0020437 \| hypercalcemia \| 1 C0153676 \| lung metastasis \| 1 C0002793 \| dedifferentiation \| 1 C0019158 \| hepatitis \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:11)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs113488022	25549141	673	BRAF	umls:C0023903	BeFree	To summarize the usefulness of several recently discovered immunohistochemical markers in the study of gastrointestinal and liver tumors; to suggest the most current and effective immunohistochemical panels addressing common diagnostic challenges for these tumors; to share practical experience and useful tips for human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinoma and v-raf murine sarcoma viral oncogene homolog B V600E immunohistochemistry in colorectal carcinoma.	0.122909916	2015	BRAF	7	140753336	A	T,G,C
rs113488022	25549141	2064	ERBB2	umls:C0023903	BeFree	To summarize the usefulness of several recently discovered immunohistochemical markers in the study of gastrointestinal and liver tumors; to suggest the most current and effective immunohistochemical panels addressing common diagnostic challenges for these tumors; to share practical experience and useful tips for human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinoma and v-raf murine sarcoma viral oncogene homolog B V600E immunohistochemistry in colorectal carcinoma.	0.001085767	2015	BRAF	7	140753336	A	T,G,C
rs13181	19919686	2068	ERCC2	umls:C0023903	GAD	[XPD codon 751 polymorphism modifies the risk of hepatocellular carcinoma]	0.002638474	2009	ERCC2;KLC3	19	45351661	T	A,G
rs199475623	17408607	4153	MBL2	umls:C0023903	BeFree	Expression analysis of the D129G mutation was performed in E. coli (expression as fusion protein MBP-PAH) and in a human hepatoma cell line with an N-terminal FLAG epitope.	0.001085767	2007	PAH	12	102877517	T	C,A
rs199475623	17408607	5053	PAH	umls:C0023903	BeFree	Expression analysis of the D129G mutation was performed in E. coli (expression as fusion protein MBP-PAH) and in a human hepatoma cell line with an N-terminal FLAG epitope.	0.001900093	2007	PAH	12	102877517	T	C,A
rs199475623	17408607	4155	MBP	umls:C0023903	BeFree	Expression analysis of the D129G mutation was performed in E. coli (expression as fusion protein MBP-PAH) and in a human hepatoma cell line with an N-terminal FLAG epitope.	0.000814326	2007	PAH	12	102877517	T	C,A
rs199475623	17408607	5553	PRG2	umls:C0023903	BeFree	Expression analysis of the D129G mutation was performed in E. coli (expression as fusion protein MBP-PAH) and in a human hepatoma cell line with an N-terminal FLAG epitope.	0.000814326	2007	PAH	12	102877517	T	C,A
rs361525	20953524	7124	TNF	umls:C0023903	GAD	[This meta-analysis supports TNF rs361525 (-238G>A) polymorphism being associated with HCC in an Asian population.]	0.158176291	2010	TNF	6	31575324	G	A
rs3811647	23588470	7018	TF	umls:C0023903	BeFree	Intronic SNP rs3811647 of the human transferrin gene modulates its expression in hepatoma cells.	0.000542884	2012	TF	3	133765185	G	A
rs430397	19533686	3309	HSPA5	umls:C0023903	GAD	[allele A and genotypes AA and AG of rs430397 may represent high risk and poor prognosis for HCC.]	0.003181358	2009	HSPA5	9	125238840	C	T
rs62508577	19629656	5053	PAH	umls:C0023903	BeFree	We analyzed p.S231F PAH protein in prokaryotic (Escherichia coli) and eukaryotic expression system (hepatoma cells).	0.001900093	2009	PAH	12	102855150	G	A

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:48)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0023903	acetaminophen	D000082	103-90-2	liver neoplasms	MESH:D008113	marker/mechanism	22084566
C0023903	s-adenosylmethionine	D012436	29908-03-0	liver neoplasms	MESH:D008113	therapeutic	12163149
C0023903	arsenic trioxide	C006632	1327-53-3	liver neoplasms	MESH:D008113	marker/mechanism	14682389
C0023903	betaine	D001622	107-43-7	liver neoplasms	MESH:D008113	therapeutic	19642983
C0023903	caffeine	D002110	1958/8/2	liver neoplasms	MESH:D008113	therapeutic	1995187
C0023903	capsaicin	D002211	404-86-4	liver neoplasms	MESH:D008113	therapeutic	1888447
C0023903	carbamazepine	D002220	298-46-4	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	cerivastatin	C086276	-	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	chlorambucil	D002699	305-03-3	liver neoplasms	MESH:D008113	therapeutic	3465877
C0023903	choline	D002794	62-49-7	liver neoplasms	MESH:D008113	marker/mechanism	3554467
C0023903	cyclophosphamide	D003520	50-18-0	liver neoplasms	MESH:D008113	therapeutic	18298334
C0023903	cisplatin	D002945	15663-27-1	liver neoplasms	MESH:D008113	therapeutic	2933968
C0023903	diethylstilbestrol	D004054	56-53-1	liver neoplasms	MESH:D008113	marker/mechanism	15890375
C0023903	epirubicin	D015251	56420-45-2	liver neoplasms	MESH:D008113	therapeutic	3465877
C0023903	floxuridine	D005467	50-91-9	liver neoplasms	MESH:D008113	therapeutic	11677951
C0023903	fluconazole	D015725	86386-73-4	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	fluorouracil	D005472	51-21-8	liver neoplasms	MESH:D008113	therapeutic	15113037
C0023903	leucovorin	D002955	1958/5/9	liver neoplasms	MESH:D008113	therapeutic	21208846
C0023903	gemcitabine	C056507	103882-84-4	liver neoplasms	MESH:D008113	therapeutic	10965557
C0023903	glutathione	D005978	70-18-8	liver neoplasms	MESH:D008113	therapeutic	7852184
C0023903	griseofulvin	D006118	126-07-8	liver neoplasms	MESH:D008113	marker/mechanism	2445643
C0023903	indomethacin	D007213	53-86-1	liver neoplasms	MESH:D008113	marker/mechanism	1477515
C0023903	lindane	D001556	58-89-9	liver neoplasms	MESH:D008113	marker/mechanism	18951770
C0023903	lovastatin	D008148	75330-75-5	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	melphalan	D008558	148-82-3	liver neoplasms	MESH:D008113	therapeutic	12606622
C0023903	methotrexate	D008727	1959/5/2	liver neoplasms	MESH:D008113	therapeutic	3465877
C0023903	methylphenidate	D008774	113-45-1	liver neoplasms	MESH:D008113	marker/mechanism	8545847
C0023903	mitomycin	D016685	1950/7/7	liver neoplasms	MESH:D008113	therapeutic	15113037
C0023903	norepinephrine	D009638	51-41-2	liver neoplasms	MESH:D008113	therapeutic	1530348
C0023903	oxaliplatin	C030110	-	liver neoplasms	MESH:D008113	therapeutic	21208846
C0023903	paclitaxel	D017239	-	liver neoplasms	MESH:D008113	therapeutic	11468447
C0023903	pantoprazole	C064276	102625-70-7	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	phenytoin	D010672	57-41-0	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	pregabalin	D000069583	-	liver neoplasms	MESH:D008113	marker/mechanism	22539615
C0023903	propranolol	D011433	525-66-6	liver neoplasms	MESH:D008113	therapeutic	19743301
C0023903	sorafenib	C471405	-	liver neoplasms	MESH:D008113	therapeutic	25489883
C0023903	spironolactone	D013148	1952/1/7	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	streptozocin	D013311	18883-66-4	liver neoplasms	MESH:D008113	marker/mechanism	2532796
C0023903	streptozocin	D013311	18883-66-4	liver neoplasms	MESH:D008113	therapeutic	227055
C0023903	toremifene	D017312	89778-26-7	liver neoplasms	MESH:D008113	marker/mechanism	7586193
C0023903	toremifene	D017312	89778-26-7	liver neoplasms	MESH:D008113	therapeutic	8402624
C0023903	triamterene	D014223	396-01-0	liver neoplasms	MESH:D008113	marker/mechanism	25058030
C0023903	troglitazone	C057693	97322-87-7	liver neoplasms	MESH:D008113	therapeutic	10503899
C0023903	vinblastine	D014747	865-21-4	liver neoplasms	MESH:D008113	therapeutic	3686684
C0023903	vinorelbine	C030852	71486-22-1	liver neoplasms	MESH:D008113	therapeutic	9849468
C0023903	vitamin a	D014801	11103-57-4	liver neoplasms	MESH:D008113	marker/mechanism	2055368
C0023903	vorinostat	C111237	-	liver neoplasms	MESH:D008113	therapeutic	17593366
C0023903	zidovudine	D015215	30516-87-1	liver neoplasms	MESH:D008113	marker/mechanism	10558926

FDA approved drug and dosage information(Total Drugs:20)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D008113	mevacor	lovastatin	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D008113	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D008113	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D008113	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D008113	eloxatin	oxaliplatin	50MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	INJECTABLE;IV (INFUSION)	Discontinued	None	Yes	No
MESH:D008113	eloxatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D008113	oxaliplatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D008113	retrovir	zidovudine	100MG	CAPSULE;ORAL	Prescription	AB	Yes	Yes
MESH:D008113	retrovir	zidovudine	50MG/5ML	SYRUP;ORAL	Prescription	AA	Yes	Yes
MESH:D008113	retrovir	zidovudine	10MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D008113	retrovir	zidovudine	200MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D008113	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D008113	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D008113	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D008113	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D008113	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D008113	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D008113	lyrica	pregabalin	25MG	CAPSULE;ORAL	Prescription	None	Yes	No
MESH:D008113	lyrica	pregabalin	25MG	CAPSULE; ORAL	Prescription	None	No	No
MESH:D008113	lyrica	pregabalin	25MG	CAPSULE; ORAL	Prescription	None	No	No

FDA labeling changes(Total Drugs:20)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D008113	02/14/2002	mevacor	lovastatin	Heterozygous Familial Hypercholesterolemia	New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age	Labeling	B	-	-	-	Merck	07/17/2001	FALSE'
MESH:D008113	6/4/2006	daytrana	methylphenidate	ADHD	Summary is pending	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D008113	12/14/2009	daytrana	methylphenidate	Postmarketing safety study	Information added to Warnings and Adverse Reactions on skin reactions observed in a postmarketing dermal study in pediatric patients	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D008113	06/29/2010	daytrana	methylphenidate	ADHD	Expanded pediatric indication to include adolescent patients ages13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of patients had erythema at the application site Information on PK parameters, Adverse Event profile and clinical studies	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D008113	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D008113	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D008113	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D008113	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	09/19/2008	retrovir syrup, capsules and tablets	zidovudine	Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection	Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D008113	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D008113	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D008113	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D008113	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D008113	12/22/2016	lyrica	pregabalin	Fibromyalgia	Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study.	Labeling	-	P	-	-	PF Prism CV	-	FALSE
MESH:D008113	12/22/2016	lyrica	pregabalin	Fibromyalgia	Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study.	Labeling	-	P	-	-	PF Prism CV	-	FALSE
MESH:D008113	12/22/2016	lyrica	pregabalin	Fibromyalgia	Safety and efficacy in pediatric patients have not been established. A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years . The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Postmarketing study.	Labeling	-	P	-	-	PF Prism CV	-	FALSE